Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients

Transplantation

Volumn 69, Issue 9, 2000, Pages 1830-1836

  Hölschermann, Hans ^a,b   Hilgendorff, Anne ^a   Kemkes Matthes, Bettina ^a   Schönburg, Markus ^a   Bauer, Erwin P ^a   Tillmanns, Harald ^a   Haberbosch, Werner ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROCOAGULANT; PROTHROMBIN; SIMVASTATIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; FEMALE; FIBRIN FORMATION; GENE EXPRESSION; GRAFT FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; LIPOPROTEIN BLOOD LEVEL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 0343183350     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005150-00017     Document Type: Article

References (44)

1. Sarris GE, Moore KA, Schroeder JS, et al. Cardiac transplantation: the Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg 1994; 108: 240.
2. Schroeder JS, Gao SZ, Hunt SA, Stinson EB. Accelerated graft coronary artery disease: diagnosis and prevention. J Heart Lung Transplant 1992; 11: S258.
3. Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenosis on survival after heart transplantation. J Heart Lung Transplant 1992; 11: 892.
4. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11: S38.
5. Faulk WP, Labarrere CA, Nelson DR, Pitts D. Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. J Heart Lung Transplant 1995; 14: S158.
6. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients: an immunocytochemical study. Circulation 1994; 89: 1599.
7. Labarrere CA, Pitts D, Nelson DR, Faulk W. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995; 333: 1111.
8. Holschermann H, Bohle RM, Zeller H, et al. In-situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am J Pathol 1999; 154: 211.
9. Hölschermann H, Kohl O, Maus U, et al. Cyclosporine inhibits monocyte tissue factor activation in cardiac transplant recipients. Circulation 1997; 96: 4232.
10. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
11. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation 1997; 96: 1398.
12. Boyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1963; 97: 77.
13. Hölschermann H, Dürfeid F, Maus U, et al. Cyclosporine A inhibits tissue factor expression in monocytes/macrophages. Blood 1996; 88: 3837.
14. Chomczynski P, Sacchi N. Single step method of RNA-isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
15. Maus U, Rosseau S, Seeger W, Lohmeyer J. Separation of human alveolar macrophages by flow cytometry. Am J Physiol 1997; 272: L566.
16. Scarpati EM, Wen D, Broze G, et al. Human tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry 1987; 26: 5234.
17. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant 1992; 11: 9.
18. Scott CD, Dark JH. Coronary disease after heart transplantation. Br Heart J 1992; 68: 255.
19. Paul C, Fellstrom B. Chronic vascular rejection of the heart and the kidney: have rational treatment options emerged? Transplantation 1992; 53: 1169.
20. Mann J. Graft vascular disease in heart transplant patients. Br Heart J 1992; 68: 253.
21. Jamieson SW. Investigation of heart transplant atherosclerosis. Circulation 1992; 85; 1211.
22. Weis M, Scheidt von W. Cardiac allograft vasculopathy. Circulation 1997; 96: 2069.
23. Adams DH, Wyner LR, Steinbeck MJ, Karnovsky MJ. Inhibition of graft arteriosclerosis by modulation of the inflammatory response. Transplant Proc 1993; 25: 2092.
24. Kuwahara M, Jacobsson J, Kuwahara M, Kagan E, Ramwell PW, Foegh ML. Coronary artery ultrastructural changes in cardiac transplant atherosclerosis in the rabbit. Transplantation 1991; 52: 759.
25. Faulk WP, Labarrere CA. Vascular immunopathology and atheroma development in human allografted organs. Arch Pathol Lab Med 1992; 116: 1337.
26. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343.
27. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1.
28. Tanaka K, Sueishi K. Biology of disease: the coagulation and fibrinolysis systems and atherosclerosis. Lab Invest 1993; 69: 5.
29. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97.
30. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 71.
31. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coagul Fibrinolysis 1993; 4: 281.
32. Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 1995; 154: 4768.
33. Valantine HA, Schroeder JS. HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms? Circulation 1997; 96: 1370.
34. Ferro D, Basili S, Alessandri C, Mantovani B, Cordova C, Violi F. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet 1997; 350: 1222.
35. Hunt FA, Rylatt DB, Hart R-A, Bendesen PG. Serum cross-linked fibrin (SDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol 1985; 60: 715.
36. Campana C, Iacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29: 235.
37. Pichard L, Fabre I, Fabre G, et al. Cyclosporine A drug interactions, screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 19: 1225.
38. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer function and other immunological parameters in men. J Clin Immunol 1993; 13: 439.
39. Kreuzer J, Bader J, Jahn L, Hautmann M, Kübler W, von Hodenberg E. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203.
40. Munro E, Patel M, Chan P, et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994; 24: 766.
41. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992; 95: 87.
42. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425.
43. Nakanishi M, Goldstein JL, Brown MS. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase: mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 1988; 263: 8929.
44. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265.